Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Escherichia coli as a Multifaceted Pathogenic and Versatile Bacterium

Vânia Santos Braz, Karine Melchior, Cristiano Gallina Moreira

Frontiers in Cellular and Infection Microbiology · 2020 · Review · CC BY

doi:10.3389/fcimb.2020.548492

Abstract

Genetic plasticity promotes evolution and a vast diversity in Escherichia coli varying from avirulent to highly pathogenic strains, including the emergence of virulent hybrid microorganism. This ability also contributes to the emergence of antimicrobial resistance. These hybrid pathogenic E. coli (HyPEC) are emergent threats, such as O104:H4 from the European outbreak in 2011, aggregative adherent bacteria with the potent Shiga-toxin. Here, we briefly revisited the details of these E. coli classic and hybrid pathogens, the increase in antimicrobial resistance in the context of a genetically empowered multifaceted and versatile bug and the growing need to advance alternative therapies to fight these infections.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Escherichia coli (or E. coli) is a Gram-negative versatile bacterium, easily found and amenable to natural and random genetic alteration. There is a vast collection of sequenced E. coli genomes which exhibit different sizes and genomic diversity among commensal and pathogens, indicating a great assortment within the same bacterial species. They comprise of non-pathogenic bacteria that may act as commensals and belong to the normal intestinal microbiota of humans and many animals. There are also pathogenic variants, divided as diarrheagenic and extraintestinal pathogens, with different pathotypes and various natural hybrid strains ( Tables 1 and 2 ). These variants can be facultative or obligate pathogens. The facultative bacteria are part of the intestinal tract and may act as opportunistic pathogens when outside of their natural habitat, causing various types of extraintestinal infections. On the other hand, intestinal obligate pathogenic variants cause infections in distinct conditions, from moderate diarrhea to more threatening cases, as lethal outcome.

E. coli pangenome studies indicate enormous capacity to evolve by gene acquisition and genetic modification. Besides, these genomes have a mosaic-like structure consisting of a core genome, encoding essential cellular functions, and an accessory genome with flexible strain-specific sequences. Thus, E. coli is a model well established for studying the interdependence of genome architecture and the lifestyle of bacteria.

Based on virulence factors in E. coli genomes and phenotypic traits, the human pathotypes of diarrheagenic E. coli (DEC) are differentiated from non-pathogenic E. coli and extraintestinal pathogenic E. coli (ExPEC). The ExPEC are classified as uropathogenic E. coli (UPEC), sepsis-causing E. coli (SEPEC) and neonatal meningitis-associated E. coli (NMEC). Recent pathogenomics and phenotypic classification have revisited the DEC group as nine distinct pathotypes, proposed by their differential features and the essential virulence genes defining each subgroup, such as Shiga toxin-producing E. coli (STEC), enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC), diffusely-adhering E. coli (DAEC), adherent-invasive E. coli (AIEC), and cell-detaching E. coli (CDEC) ( Table 1 ).

Herein, we briefly describe the diversity of these classic and novel emerging E. coli pathotypes and their genetic plasticity in a multifaceted organism. The mobile genetic elements are responsible for the appearance of novel hybrid strains with distinct assortment of virulence and antimicrobial resistance traits, bringing up the urgent need to reconsider the forms of treatment for these infections.

Types of E. coli: Many Flavors Within a Single Bacterial Species

E. coli is one of the most genetically versatile microorganisms and is able to colonize and persist in several niches, both in the environment or in hosts. Commensal E. coli strains colonize the gastrointestinal tract of humans a few hours after birth, resulting in a symbiotic relationship between the microbiota and its host. However, the mechanisms by which E. coli ensures this efficient symbiosis is not well known. It could be related to its high ability to use nutrients in the colon. Several studies have shown that competition for nutrients between microbiota and pathogens limits the colonization of the pathogens, leading to fierce competition among these microorganisms.

Occasionally, pathogenic E. coli cannot be distinguished from commensal E. coli, only based on specific virulence factors, as some previously described in ExPEC strains. However, this scenario is changing due to sophistication and availability of molecular typing methodologies. New computational approaches bring countless important information about host-pathogen relationships, reservoir, clinical diagnoses, and novel ExPEC transmission pathways. Often, virulence genes are located in transmissible genetic elements such as genomic islands, bacteriophages, insertion sequences (ISs), integrons, plasmids, and transposons; hence, they can be easily exchanged among different bacteria. They also carry multiple antibiotic resistance genes that have been under strong selective pressure as consequence of the extensive use of antibiotics.

Common genetic changes in E. coli genomes ensure high diversity due to the gain and loss of genes through genetic modification events. There are many strains of ExPEC that normally colonize the gut asymptomatically, as members of the intestinal microbiota. Nonetheless, only a subset of ExPEC as UPEC, SEPEC and NMEC are responsible for the vast majority of infections such as urinary tract infections, sepsis, and meningitis. There is a great variety of virulence factors in ExPEC strains, such as adhesins (fimbrial and non-fimbrial), siderophores, toxins, invasins, the ability to survive in serum, among others. Moreover, many of these virulence factors may occur combined within the same strain and act synergistically. Despite extra factors, the septic strains always possess at least an adherence system, an iron uptake system and genes for serum survival ( Table 1 ).

The genetic evolution in E. coli pathogenesis employs horizontal transfer mechanisms within same and across similar species. Therefore, the IS, transposons and integrons may facilitate novel rearrangements within the genome, such as duplication and suppression of genes and also capture of new genes. This genetic material transit can result in greater flexibility concerning various features, such as the transition of pathogenic bacteria between humans and animals, resistance to antimicrobials, appearance of emerging pathogens due to the gain of virulence genes, increased pathogenicity, among other features. All these conditions may contribute to the virulence of these bacteria, like the bacteriophage importance in the pathogenesis. The horizontal transfer between different strains favors the emergence of new pathogenic strains with discrepancies in the bacteriophage repertoire affecting directly their virulence.

The co-evolution of bacterial genomes with plasmids, besides potential genetic and phenotypic gain may impact cellular metabolism to ensure the maintenance and stability of the plasmid. Many ExPEC virulence genes are encoded within plasmids, often belonging to the ColV family, which encodes colicin, serum survival factors and iron uptake systems. Similarly, intestinal pathogens carry a variety of types of plasmids, associated with virulence, majorly belonging to the incompatibility group IncF, which has transfer functions. There are virulence plasmids essential for some pathotypes of E. coli, such as pINV and pAA, respectively, in EIEC and EAEC, according to each own group features.

Although, all ExPEC and DEC pathotypes are not enough to fully classify all pathogenic E. coli strains, since these bacteria are so variable, allowing constant appearance of distinct hybrid-formed strains within this dynamic bacterial species. The carriage of virulence genes essential to the pathogenesis of each pathotype and the ability to adapt to different conditions allow the emergence of hybrid pathogenic E. coli (HyPEC).

Genetic Plasticity and Emergent E. coli Pathogen: HyPEC

E. coli has an astonishing facility to amend very well, replicate and disseminate. These features allowed the advent of novel HyPEC. Acquired virulence genes and novel functions appear from mutation, recombination and other genetic changes. All these genetic differences have increased the occurrence of novel hybrid and antimicrobial resistance among DEC and ExPEC.

Recently, a HyPEC strain received widespread attention after an outbreak of foodborne bloody diarrhea and hemorrhagic uremic syndrome (HUS) in Germany. This outbreak of E. coli O1O4:H4 was associated with consumption of raw fenugreek sprouts, as a hybrid EAEC strain with STEC features, like Shiga toxin presence. This HyPEC was quickly sequenced and unraveled its intricate nature, but even with a quick response and identification it was not enough to avoid 3,842 hospitalizations with many fatalities in Europe and North Africa. Emerging processes are responsible for the HyPEC occurrences. Herein, the combined enteroaggregative features in a rare serotype was responsible to high attachment to cells and a biofilm formation. Moreover, this strain has gained stx2 gene lambdoid phage integrated in the genome, thus it may release the Shiga-toxin. These features have increased HUS occurrence during the outbreak on this HyPEC when compared to STEC.

Many distinct genetic hybrid examples are reported in E. coli, such as STEC/ExPEC O80:H2 serotype, which caused HUS and bacteremia due the presence of stx2 and eae genes from STECs and pS88-like plasmid, described in meningitis, urosepsis and avian pathogenic strains of ExPEC. The STEC/UPEC strain O2:H6 serotype, a STEC with virulence genes as α-hlyA, cnf1, and clb from UPEC that have ability to cause diarrhea and urinary tract infections. The EPEC/ETEC strain has acquired the LEE island and encodes the LT toxin. The broadly reported multidrug resistant E. coli ST131 is example of highly virulent ExPEC associated with urinary and bloodstream infections. It has also acquired enteroaggregative diarrheagenic phenotype due to pAA plasmid presence. Many others HyPEC are described as case report, but not fully characterized. Here, we have briefly sampled some of the acquired genes by these strains, their direct impact in virulence and their hybrid nature ( Table 2 ). Comparable to these HyPEC, the coined terms hybrid- and hetero-pathogenic E. coli have been recently described as new combination of virulence factors among classic E. coli groups. Together, they show differences between typical and atypical subgroups within the EAEC and EPEC pathotypes and hybrids, such as EPEC/STEC, ExPEC/EPEC and ExPEC/EAEC hybrids. Similar to our approach here, this study shows how this topic is critical in the field.

The high prevalence of classic pathogenic E. coli and appearance of HyPEC occur via similar genetic mechanisms, which also enable bacteria to resist the presence of distinct antimicrobials. Bacteria resistant to various classes of antibiotics are related to the complex combination of intrinsic and acquired resistance genes, which may act synergistically. Together that brings multiresistant bacteria, as an alarming factor reported worldwide in several bacterial species. WHO has prioritized studies on AMR bacteria, including Enterobacteriaceae, based on recent surveillance reports.

Emerging Hybrids and Alternative Therapies

The complex combination of multidrug-resistant bacteria and emerging hybrid bacteria with intrinsic or acquired bacterial virulence factors disseminated by genetic mobility elements, the intense and inappropriate use of antibiotics have simultaneously favored the emergence of resistance to various antibiotics. That is a special challenge to these hybrid strains, since these HyPEC gathered virulence traits and acquired antibiotic resistance, together these points raise the importance to alternative treatments. These options are crucial to reduce the use of antibiotics and the consequent increase of antimicrobial resistance. Novel therapies are urgent to replace prophylactic and treatment with antibiotics by probiotics, prebiotics, enzymatic compounds, vaccines, monoclonal antibodies, phage therapy, antivirulence compounds, among other possibilities.

Recently, different vaccine strategies have been used for pathogenic E. coli infection as an alternative to antibiotic therapy, including vaccines with attenuated toxins, attenuated bacterial cell, individual components of virulence factors such as Shiga toxin, EspA or Intimin, small peptides, DNA or polysaccharides, as well detailed in the literature. Commercial vaccines have aimed the use to protect livestock, such as poultry, swine and bovine herds, against respectively to APEC, like Poulvac® E. coli, ETEC and EHEC infections. Vaccines with a modern approach and technology still are a promising strategy to protect against emergent HyPECs infections in humans and livestock.

Recent studies have revisited the phage therapy as a biological alternative, which employs strictly lytic phages uncapable of lysogenization. Studies have demonstrated ability of phages to decrease biofilm formation in UPEC, increased mice rate survival in E. coli-induced pneumonia. Moreover, lytic bacteriophages were used to infect and kill bacteria harboring phage-dependent conjugative plasmid to avoid emergence of multiresistant bacteria. The phages cocktail EcoShield™ is already commercialized (Intralytix) and it has been reported to significantly reduce the E. coli O157:H7 contamination on surfaces and food. Additionally, mutual use of phages with antibiotics have emerged, with SPR02 and DAF6 phages combined with enrofloxacin have shown promising data, rescuing chickens challenged with avian pathogenic E. coli infection.

The novel approach via antivirulence-directed compounds works disarming the pathogens’ ability to cause disease by inhibiting their virulence factors, favoring the host’s immune defenses during the bacterial clearance. These compounds do not induce bacterial resistance as antibiotics, because they disarm the pathogen, instead of directly targeting its growth. Therefore, as they are directed to specific factors for pathogenesis, they potentially reduce the selection of resistance and limit collateral damage to the microbiota. Some virulence inhibitors are effective against many pathogens, molecules such as LED209, HC102A, HC103A, Artemisinin, and Ethoxzolamide, by inhibit different two-component systems as QseBC in E. coli and other enteropathogens, Bicyclic 2-pyridones, Biaryl mannoside, Nitazoxanide and FN075, avoiding the initial bacterial adhesion; and compounds like Toxtazins A and B, Ebselen, 7086, 7812, 7832, BPT15, and BBH7, blocking toxins and secretion systems.

Conclusion

The forces that shape the evolution in E. coli comprise vast repertoire, affecting genetic flexibility and excessive permissiveness to acquire and donate DNA via horizontal gene transfer. These features guarantee the spread of antibiotic resistance as well as virulence factors inherited among the various pathotypes of E. coli. The exact identification and assessment assist researchers to better understand this bacterium modification, diagnosis, public health and treatment. E. coli strains with multiple and distinct factors are probably very common but unreported, since these E. coli strains have developed many strategies to persist in different settings and successfully infect the host. These strategies result in an immense variety of microorganisms, ranging from avirulent to extremely virulent strains that can cause intestinal or extraintestinal diseases. E. coli strains have great potential for dissemination and capacity to pass along hereditary elements. Currently, these HyPEC strains are a very concerning threat that demands more studies and the development of novel treatment methods.

Author Contributions

VB: writing and organization. KM: writing. CM: writing and mentoring. All authors contributed to the article and approved the submitted version.

Funding

Financially supported by FAPESP (grants 2014/06779-2, 2018/22412-2, 2018/22042-0, and 2019/03049-7), CNPq (307418/2017-0), and “Programa de Apoio ao Desenvolvimento Científico da Faculdade de Ciências Farmacêuticas da UNESP-PADC. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 109

  1. 1.

    Abuladze T. Li M. Menetrez M. Y. Dean T. Senecal A. Sulakvelidze A. (2008 ). Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl. Environ. Microbiol. 74, 6230–62 8.

    Not in our library10.1128/aem.01465-08.21

  2. 2.

    Ahmed A. Li J. Shiloach Y. Robbins J. B. Szu S. C. (2006 ). Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J. Infect. Dis. 193, 515–521.

    Not in our library10.1086/499821

  3. 3.

    Aslani M. M. Alikhani M. Y. Zavari A. Yousefi R. Zamani A. R. (2011 ). Characterization of enteroaggregative Escherichia coli (EAEC) clinical isolates and their antibiotic resistance pattern. Int. J. Infect. Dis. IJID Off. Publ. Intern. Soc Infec. Dis. 15 (2), e136–e139.

    Not in our library10.1016/j.ijid.2010.10.002

  4. 4.

    Barrios-Villa E. Cortés-Cortés G. Lozano-Zaraín P. Arenas-Hernández M. Martínez de la Peña C. F. Martínez-Laguna Y. (2018 ). Adherent/invasive Escherichia coli (AIEC) isolates from asymptomatic people: new E. coli ST131 O25:H4/H30-Rx virotypes. Ann. Clin. Mic. Antim. 17 (1), 42.

    Not in our library10.1186/s12941-018-0295-4

  5. 5.

    Baylis C. L. Penn C. W. Thielman N. M. Guerrant R. L. Jenkins C. Gillespie S. H. (2006 ). “Escherichia coli and Shigella spp,” in Principles and Practice of Clinical Bacteriology, 2nd ed. Eds. Gillespie S. H. Hawkey P. M. (England, UK: John Wiley and Sons Ltd), 347–365.

    Not in our library10.1002/9780470017968.ch28

  6. 6.

    Bielaszewska M. Dobrindt U. Gärtner J. Gallitz I. Hacker J. Karch J. (2007 ). Aspects of genome plasticity in pathogenic Escherichia coli. Int. J. Med. Microbiol. 297 (7-8), 625–639.

    Not in our library10.1016/j.ijmm.2007.03.001

  7. 7.

    Bielaszewska M. Mellmann A. Zhang W. Köck R. Fruth A. Bauwens A. (2011 ). Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in German: a microbiological study. Lancet Infect. Dis. 11 (9), 671–676.

    Not in our library10.1016/s1473-3099(11)70165-7

  8. 8.

    Bielaszewska M. Schiller R. Lammers L. Bauwens A. Fruth A. Middendorf B. (2014 ). Heteropathogenic virulence and phylogeny reveal phased pathogenic metamorphosis in Escherichia coli O2:H6. EMBO Mol. Med. 6, 347–357.

    Not in our library10.1002/emmm.201303133

  9. 9.

    Biran D. Ron E. Z. (2018 ). Extraintestinal Pathogenic Escherichia coli. Curr. Top. Microbiol. Immunol. 416, 149–161.

    Not in our library10.1007/82_2018_108

  10. 10.

    Bitzan M. Poole R. Mehran M. Sicard E. Brockus C. Thuning-Roberson C. (2009 ). Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob. Agents Chemother. 53, 3081–3087.

    Not in our library10.1128/aac.01661-08

  11. 11.

    Boll E. J. Overballe-Petersen S. Hasman H. Roer L. Ng K. Scheutz F. (2018 ). Emergence of enteroaggregativeEscherichia coli within the ST131 lineage as a cause of extraintestinal infections. mBio 11 (3), e00353–e00420.

    Not in our library10.1128/mbio.00353-20

  12. 12.

    Brigulla M. Wackernagel W. (2010 ). Molecular aspects of gene transfer and foreign DNA acquisition in prokaryotes with regard to safety issues. Appl. Microbiol. Biotechnol. 86 (4), 1027–1041.

    Not in our library10.1007/s00253-010-2489-3

  13. 13.

    Brzuszkiewicz E. Gottschalk G. Ron E. Hacker J. Dobrindt U. (2009 ). Adaptation of Pathogenic E. coli to Various Niches: Genome Flexibility is the Key. Genome Dyn. 6, 110–125.

    Not in our library10.1159/000235766

  14. 14.

    Cag Y. Caskurlu H. Fan Y. Cao B. Vahaboglu H. (2016 ). Resistance mechanisms. Ann. Transl. Med. 4 (17), 326.

    Not in our library10.21037/atm.2016.09.14

  15. 15.

    Calderon Toledo C. Arvidsson I. Karpman D. (2011 ). Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model. Infect. Immun. 79, 2224–2233.

    Not in our library10.1128/iai.01024-10

  16. 16.

    Carattoli A. (2009 ). Resistance plasmid families in Enterobacteriaceae. Ant. Agents Chemother. 53 (6), 2227–2238.

    Not in our library10.1128/aac.01707-08

  17. 17.

    Carattoli A. (2013 ). Plasmids and the spread of resistance. Int. J. Med. Microbiol. 303, 298–304.

    Not in our library10.1016/j.ijmm.2013.02.001

  18. 18.

    Carter C. D. Parks A. Abuladze T. Li M. Woolston J. Magnone J. (2012 ). Bacteriophage cocktail significantly reduces Escherichia coli O157: H7 contamination of lettuce and beef, but does not protect against recontamination. Bacteriophage 2 (3), 178–185.

    Not in our library10.4161/bact.22825

  19. 19.

    Chahales P. Hoffman P. S. Thanassi D. G. (2016 ). Nitazoxanide Inhibits Pilus Biogenesis by Interfering with Folding of the Usher Protein in the Outer Membrane. Antimicrob. Agents Chemother. 60, 2028–2038.

    Not in our library10.1128/aac.02221-15

  20. 20.

    Chattaway M. A. Day M. Mtwale J. White E. Rogers J. Day M. (2017 ). Clonality, virulence and antimicrobial resistance of enteroaggregative Escherichia coli from Mirzapur, Bangladesh. J. Med. Microbiol. 66 (10), 1429–1435.

    Not in our library10.1099/jmm.0.000594

  21. 21.

    Chibeu A. Lingohr E. J. Masson L. Manges A. Harel J. Ackermann H.-W. (2012 ). Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses 4, 471–487.

    Not in our library10.3390/v4040471

  22. 22.

    Curtis M. M. Russell R. Moreira C. G. Adebesin A. M. Wang C. Williams N. S. (2014 ). QseC inhibitors as an antivirulence approach for Gram-negative pathogens. MBio 5 (6), e02165.

    Not in our library10.1128/mbio.02165-14

  23. 23.

    Day M. Doumith M. Jenkins C. Dallman T. J. Hopkins K. L. Elson R. (2017 ). Antimicrobial resistance in Shiga toxin-producing Escherichia coli serogroups O157 and O26 isolated from human cases of diarrhoeal disease in Englan. J. Antimicrob. Chemother. 72 (1), 145–152.

    Not in our library10.1093/jac/dkw371

  24. 24.

    Dobrindt U. Agerer F. Michaelis K. Janka A. Buchrieser C. Samuelson M. (2003 ). Analysis of genome plasticity in pathogenic and commensal Escherichia coli isolates by use of DNA arrays. J. Bacteriol. 185 (6), 1831–1840.

    Not in our library10.1128/jb.185.6.1831-1840.2003

  25. 25.

    Dobrindt U. Chowdary M. G. Krumbholz G. Hacker J. (2010 ). Genome dynamics and its impact on evolution of Escherichia coli. Med. Microbiol. Immunol. 199 (3), 145–154.

    Not in our library10.1007/s00430-010-0161-2

  26. 26.

    Ducarmon Q. R. Zwittink R. D. Hornung B. V. H. van Schaik W. Young V. B. Kuijper E. J. (2019 ). Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. Microbiol. Mol. Biol. Rev. 83 (3), e00007–e00019.

    Not in our library10.1128/mmbr.00007-19

  27. 27.

    Dufour N. Debarbieux L. Fromentin M. Ricard J. D. (2015 ). Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit. Care Med. 43 (6), e190–e198.

    Not in our library10.1097/ccm.0000000000000968

  28. 28.

    Dutta S. Pazhani G. P. Nataro J. P. Ramamurthy T. (2015 ). Heterogenic virulence in a diarrheagenic Escherichia coli: evidence for an EPEC expressing heat-labile toxin of ETEC. Int. J. Med. Microbiol. 305, 47–54.

    Not in our library10.1016/j.ijmm.2014.10.006

  29. 29.
  30. 30.

    Elliott S. J. Srinivas S. Albert M. J. Alam K. Robins-Browne R. M. Gunzburg S. T. (1998 ). Characterization of the roles of hemolysin and other toxins in enteropathy caused by alpha-hemolytic Escherichia coli linked to human diarrhea. Infect. Immun. 66, 2040–2051.

    Not in our library10.1128/iai.66.5.2040-2051.1998

  31. 31.

    Fabich A. J. Jones S. A. Chowdhury F. Z. Cernosek A. Anderson A. Smalley D. (2008 ). Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine. Infect. Immun. 76, 1143–1152.

    Not in our library10.1128/iai.01386-07

  32. 32.

    Fábrega V. L. A. Ferreira A. J. P. Patrício F. R. S. Brinkley C. Scaletsky I. C. A. (2002 ). Cell-detaching Escherichia coli(CDEC) strains from children with diarrhea: Identification of a protein with toxigenic activity. FEMS Microbiol. Lett. 217 (2), 191–197.

    Not in our library10.1111/j.1574-6968.2002.tb11474.x

  33. 33.

    Fernandes M. R. McCulloch J. A. Vianello M. A. Moura Q. Perez-Chaparro P. J. Esposito F. (2016 ). First Report of the Globally Disseminated IncX4 Plasmid Carrying the mcr-1 Gene in a Colistin-Resistant Escherichia coli Sequence Type 101 Isolate from a Human Infection in Brazil. Antimic. Agents Chemother. 60 (10), 6415–6417.

    Not in our library10.1128/aac.01325-16

  34. 34.

    Frost L. S. Leplae R. Summers A. O. Toussaint A. (2005 ). Mobile genetic elements: the agents of open source evolution. Nat. Rev. Microbiol. 3 (9), 722–732.

    Not in our library10.1038/nrmicro1235

  35. 35.

    Gadde U. Kim W. H. Oh S. T. Lillehoj H. S. (2017 ). Alternatives to antibiotics for maximizing growth performance and feed efficiency in poultry: a review. Anim. Health Res. Rev. 18 (1), 26–45.

    Not in our library10.1017/s1466252316000207

  36. 36.

    García-Angulo V. A. Kalita A. Kalita M. Lozano L. Torres A. G. (2014 ). Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7. Infect. Immun. 82, 2016–2026.

    Not in our library10.1128/iai.01437-13

  37. 37.

    Garmendia J. Frankel G. Crepin V. F. (2005 ). Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation. Infect. Immun. 73 (5), 2573–2585.

    Not in our library10.1128/iai.73.5.2573-2585.2005

  38. 38.

    Gioia-Di Chiacchio R. M. Cunha M. P. V. de Sá L. R. M. Davies Y. M. Pereira C. B. P. Martins F. H. (2018 ). Novel Hybrid of Typical Enteropathogenic Escherichia coli and Shiga-Toxin-Producing E. coli (tEPEC/STEC) Emerging From Pet Birds. Front. Microbiol. 9:2975:2975.

    Not in our library10.3389/fmicb.2018.02975

  39. 39.

    Gomes T. A. Elias W. P. Scaletsky I. C. Guth B. E. Rodrigues J. F. Piazza R. M. (2016 ). Diarrheagenic Escherichia coli. Braz. J. Microbiol. 47 Suppl 1, 3–30.

    Not in our library10.1016/j.bjm.2016.10.015

  40. 40.

    Gunzburg S. T. Chang B. J. Elliott S. J. Burke V. Gracey M. (1993 ). Diffuse and enteroaggregative patterns of adherence of enteric Escherichia coli isolated from aboriginal children from the Kimberley region of Western Australia. J. Infect. Dis. 167, 755–758.

    Not in our library10.1093/infdis/167.3.755

All 109 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.